必赢体育app下载,必赢体育

官方QQ
官方微信
手机版
您的位置:首页 >硕士生导师>中药化学方向>详细内容

中药化学方向

鲁军

       e2f5a2d4d9334b2e85b3aff95b1a8f32.Png

一、个人简介

鲁军,必赢体育app下载,必赢体育教授,硕士/博士生导师,博士后合作导师;香港浸会大学中医药学院博士/博士后,任职于必赢体育app下载,必赢体育药学院。四川省高层次引进人才,省部级优秀人才计划入选者,四川省杰出青年科技人才,四川省创业领军人才。在Nature Aging, Nature Communications, Advanced Science, Journal of Advanced Research, Chemical Engineering Journal等国际期刊发表SCI论文70余篇,申请多项中国和美国发明专利,并已授权专利18项。主持国家自然基金面上项目、青年项目、四川省杰出青年基金及地区基金10余项。

联系方式:ljaaa111@163.com

研究方向:

1天然药物合成方向

基于增效减毒的目的,对具有潜在生物活性的中药单体成分或是高毒性的天然药物成分进行结构修饰,获取新型药物分子,并进行药理学评价;

基于手性小分子催化剂,开发新型催化剂以及构建新的合成方法,用于建立具有开发和应用前景的药物分子库。

2靶向药物制剂方向

靶向抗肿瘤功能性大分子(包括核酸、多肽、多糖等具有特殊功能性的大分子)-活性天然药物偶联物的设计、合成以及药理学评价;

多功能自组装纳米药物的设计、合成以及药理学评价。

3肿瘤免疫药理学方向

针对肿瘤、炎症等相关疾病开发的新型药物分子或是活性天然产物,评价其生物活性并阐明作用机制。

 

二、代表性成果

承担项目

1.国家自然科学基金委员会,面上项目,82273812,核酸适配体-多价喜树碱偶联物的设计、合成及其EGFR介导的靶向抗肿瘤活性研究,主持

2.四川省自然科学基金,杰出青年科学基金,23NSFJQ0099,GSH驱动智能型EGFR核酸适配体多价喜树碱偶联物“精准狙击”非小细胞肺癌的研究,主持

3.中央引导地方-自由探索项目,24ZYZYTS0233,基于EGFR变构位点的智能响应型核酸适配体-PROTAC偶联物解锁NSCLC双重靶向新疗法,主持

近期发表部分论文

1.Zeng Y., Cao Y., Ren S., Zhang C., Liu J., Liu K. Jun Lu*. Responsive ROS-Augmented Prodrug Hybridization Nanoassemblies for Multidimensionally Synergitic Treatment of Hepatocellular Carcinoma in Cascade Assaults. Advanced science, 2025, e2501420.

2.Zhang C., Chen Y., Zuo Y., Wang M., Chen H., Wang C. Jun Lu*. Dual targeting of FR+ CD44 overexpressing tumors by self-assembled nanoparticles quantitatively conjugating folic acid-hyaluronic acid to the GSH-sensitively modified podophyllotoxin. Chemical Engineering Journal, 2025, 505, 159276.

3.Liu C., Cao Y., Zuo Y., Zhang C., Ren S., Zhang X., Jun Lu*. Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors. Journal of Advanced Research, 2025, 68: 459-475.

4.Chen Y., Chen Y., Xu H., Liu J., Wang Y., Zeng Y., Jun Lu*. GSH-Responsive Heterodimeric Dual-Targeted Nanomedicine Modulates EMT to Conquer Paclitaxel-Induced Invasive Breast Cancer Metastasis. Bioconjugate Chemistry. 2025.

5.Cheng X., Wang Y., Zhang T., Cao Y., Cheng H., Du Y., Jun Lu*. Emergence of Small Nucleic Acids as Drugs in Precision Medicine. Clinical Pharmacology & Therapeutics, 2025.

6.Wang C., Xu H., Chen Y., Li X., Chen H., Liu J., Jun Lu*. Hydroxyl-based acid-hypersensitive acetal ester bond: Design, synthesis and the application potential in nanodrugs. European Journal of Medicinal Chemistry, 2024, 117153.

7.Chen Y., Yang J., Wang C., Wang T., Zeng Y., Li X., Jun Lu*. Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer. Journal of Experimental & Clinical Cancer Research, 2024, 43, 207.

8.Zhang X, Chen Y, Li X, Jun Lu*. Carrier-free self-assembled nanomedicine based on celastrol and galactose for targeting therapy of hepatocellular carcinoma via inducing ferroptosis. European Journal of Medicinal Chemistry, 2024, 116183.

9.Xie Q., Chen Y., Li C., Cao X., Jun Lu*. Ionizable copolymer functionalized magnetic nanocomposite as an adsorbent for boosting the extraction selectivity of aristolochic acids[J]. Journal of Food and Drug Analysis, 2024, 32, 65.

10.Ling J., Li X., Wang M., Zhang C., Liu Y., Zhang X. Jun Lu*. Novel sulfonyl-substituted tetrandrine derivatives for colon cancer treatment by inducing mitochondrial apoptosis and inhibiting PI3K/AKT/mTOR pathway. Bioorganic Chemistry, 2023: 107069.

11.Geng Q., Liu B., Fan D., Cao Z., Li L., Lu P., Jun Lu*. Strictosamide ameliorates LPS-induced acute lung injury by targeting ERK2 and mediating NF-κB signaling pathway. Journal of Ethnopharmacology, 2023: 117593.

12.Li X., Liu C., Zhang X., Sun C., Ling J., Liu Y., Jun Lu*. Bruceine A: Suppressing metastasis via MEK/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer. Biomedicine & Pharmacotherapy, 2023, 168: 115784.

13.Cao X, Luo Y, Liu X, Shang C, Jun Lu* Aptamer-thrombin loaded magnetic microspheres for bio-specific extraction and precise detection of hirudin[J]. Talanta, 2023: 125244.

14.Zhang C., Cao Y., Zuo Y., Cheng H., Liu C., Xia X., Jun Lu*. Bruceine a exerts antitumor effect against colon cancer by accumulating ROS and suppressing PI3K/Akt pathway. Frontiers in Pharmacology, 2023, 14, 1149478.

15.Yiru Pu, Yi Zuo, Jie Ling, Meimei Li, Hui Huang, Jun Lu*. Carbene-catalyzed kinetic resolution of bispirooxindoles: selective lactam amidation and access to challenging chiral scaffolds. Organic Chemistry Frontiers, 2023, 10, 1230-1236.

终审:药学院总管理账号